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Background 
Airway hyperresponsiveness (AHR) is a hallmark of 
persistent asthma and may be measured using direct histamine 
or indirect mannitol challenge. Direct airway challenges, 
using agents such as methacholine and histamine, are highly 
sensitive but not particularly speci ic for the detection of 
asthma [1]. They act directly by causing airway smooth 
muscle constriction resulting in reduced airway calibre. 
Indirect airway challenges such as mannitol and adenosine 
monophosphate (AMP) act by causing release of endogenous 
mediators such as leukotrienes and histamine which in turn 
stimulate airway smooth muscle constriction with or without 
microvascular leakage [2]. 
AHR is useful to clinicians as its severity correlates well 
with asthma severity and the amount of treatment required to 
control symptoms. AHR has traditionally been characterised 
by increased sensitivity to constrictor agents, a steeper slope 
of the dose response curve and a greater maximal response 
overall [3]. 
To better understand the concept of AHR, it can be 
useful to further divide its components into persistent and 
variable factors. Persistent factors are largely a consequence 
of structural airway changes including subendothelial 
thickening, smooth muscle hypertrophy, matrix deposition 
and vascular changes. These alterations in airway geometry 
are associated with a greater degree of airway constriction 
when stimulated by contractile agents. The more variable 
portion of AHR is thought to be related to and in luenced 
by environmental factors such as allergens, respiratory 
infections and treatment [4]. It is well recognised that airway 
in lammation and remodelling are associated with AHR [5]. 
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Additionally, AHR is associated with peripheral blood 
eosinophilia in asymptomatic individuals [6]. The degree 
of AHR correlates with sputum eosinophils, a steeper FEV1 
decline, disease severity and worse reported symptoms [7-
9]. We have previously reported on the relationship between 
airway geometry and inhaled corticosteroid (ICS) dose to AHR 
using methacholine and AMP [10]. 
We therefore performed a retrospective analysis of 
our Scottish database of asthma patients with the aim to 
investigate the relationship between ICS dose, allergy and 
baseline spirometry to AHR. Furthermore, we explored 
the putative connection between type 2 in lammatory (T2) 
biomarkers and AHR. Instead of methacholine and AMP as in 
our previous study [10], we used histamine and mannitol for 
our challenge agents. 
Methods 
Database 
The database consisted of 131 patients with known 
persistent asthma taking ICS, recruited retrospectively 
from the Scottish Centre for Respiratory Research who had 
previously attended for screening into clinical trials or had 
attended a National Health Service (NHS) specialist respiratory 
clinic. All patients had physician-diagnosed asthma based 
on history and objective testing and were all taking inhaled 
corticosteroid. As part of their clinical trial, patients were 
characterised according to spirometry, skin prick allergy 
testing, histamine or mannitol challenge testing, FeNO and 
blood eosinophil count. Instead of skin prick testing, NHS 
patients underwent blood sampling for allergen speci ic IgE 
testing i.e. radioallergosorbent testing (RAST). T2 biomarkers 
were obtained within 6 months of airway challenge testing. 
Spirometry 
Spirometry (Micromedical, Chatham, UK) was performed 
according to American Thoracic Society (ATS) and European 
Respiratory Society (ERS) guidelines [11]. Prior to attending 
the laboratory for spirometry and airway challenge, patients 
had been asked not to use their short acting beta-2 agonists 
for 6 hours, long acting beta-2 agonists and muscarinic 
antagonists, theophyllines and leukotriene receptor 
antagonists for 48 hours. 
Allergy testing 
Skin reactivity to common aeroallergens (grasses, trees, 
house dust mite, aspergillus, dog and cat) was determined with 
skin prick tests (Diagenics Ltd, Milton Keynes, UK) on the volar 
aspect of the forearm, using a standard puncture technique 
[12]. Saline solution (0.9%) and histamine (1 mg/ml) were 
used as negative and positive controls, respectively. Wheal 
and lare size were measured 15 minutes after administration 
of allergens and a positive reaction was deemed 2mm or 
larger than negative control. 
Blood testing was performed to detect presence of 
circulating levels of speci ic IgE antibodies to de ined common 
allergens [Fluorescence enzyme linked immunoassay 
(Phadia Immunocap 250)]. In our NHS laboratory a speci ic 
IgE concentration greater than 0.35 kUA/L is considered a 
positive RAST test. We characterised allergy as the number of 
positive skin or RAST responses in an individual. 
Fractional exhaled Nitric Oxide 
FeNO was measured using NIOX MINO or VERO (Circassia, 
Oxford, UK) according to manufacturer’s instructions and 
ATS/ERS guidelines [13]. 
Bronchial challenge 
Histamine was dispensed via nebuliser solution (Tayside 
Pharmaceuticals, Dundee, UK) and airway challenge 
was performed using a Mefar dosimeter with doubling 
concentrations up to a maximum of 32 mg/ml in accordance 
with ATS guidelines. The provocative concentration of 
histamine required to cause a 20% fall in FEV1 (PC20) was 
calculated by logarithmic interpolation of the log dose-
response curve. A positive challenge was considered to be a 
PC20 < 8 mg/ml. Mannitol was given via dry powder inhaler 
(Aridol, Pharmaxis Ltd, Sydney, Australia) in dose increments 
up to a maximum cumulative dose of 635 mg until a fall 
in FEV1 of 15% from baseline was achieved. The mannitol 
cumulative dose resulting in a 15% fall in FEV1 (PD15) was 
calculated by linear interpolation of the log dose-response 
curve as previously described, with a value of < 635 mg 
being considered a positive test [14]. We elected to use the 
same threshold sensitivity values for mannitol and histamine 
challenges as previously reported [15]. 
Statistical analysis 
Data were irst analysed for normality with Shapiro-
Wilk tests and Boxplots. Data for FeNO were logarithmically 
transformed to normalise the distribution prior to analysis. 
Independent Student’s T tests with alpha error set at 0.05 
(2-tailed) were used to determine differences in FeNO, FEV1, 
FEF25-75 and allergy according to AHR status i.e. positive vs. 
negative tests. Receiver operator characteristic (ROC) curves 
were also plotted to evaluate sensitivity and speci icity of 
FeNO for detecting pre-test probability of AHR. We calculated 
a beclomethasone equivalent daily ICS dose for the purposes 
of analysis. Analysis was performed using Statistical Products 
and Service Solutions (SPSS) for Windows Version 25 by 
International Business Machines Corporation (IBM). 
Ethics 
Caldicott Guardian approval was obtained to allow access 
to any National Health Service patient identi iable data 
including allergy, airway challenge testing, blood eosinophils, 
FeNO and spirometry. 
All clinical trial patients consented to use of their data. 
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Results 
131 patients taking ICS, presenting with a known diagnosis 
of persistent asthma over a 2-year period were entered into 
the database. Demographic data are shown in table 1. Of these, 
75 had a histamine challenge and 56 underwent a mannitol 
challenge with 73/115 (63%) of subjects being characterised 
as allergic on the basis of at least one positive skin prick or 
RAST to a common aeroallergen panel. In the combined group, 
all patients were taking ICS at a mean daily dose of 858 μg; 
55/131 (42%) were taking a long acting beta-2 receptor 
agonist; 16/131 (12%) were taking a long acting muscarinic 
antagonist; 32/131 (24%) were taking a leukotriene receptor 
antagonist and 3/131 (2%) were taking theophylline. For 
combined challenges, there were 75/131 (57%) patients who 
had a positive test. ICS mean (SEM) dose was signi icantly lower 
in patients with AHR +ve vs. AHR -ve: 459(54) vs. 550(73) in 
the combined group (p < 0.01); 776(67) vs. 1,026(95) in the 
histamine subgroup (p < 0.05) and 694(86) vs. 995(119) in 
the mannitol subgroup (  < 0.05). 
Both FEV1 % and FEF25-75 % were signi icantly lower in 
patients with positive versus negative AHR (Table 2) when the 
challenges were combined (Figure 2), and also for histamine 
responders on their own. FeNO was shown in combined 
(Figure 2), histamine and mannitol groups to be signi icantly 
higher in patients with AHR compared to those without. 
Patients with AHR demonstrated a signi icantly higher 
allergic burden (Figure 2) in terms of number of positive skin 
or RAST responses. This difference was largely attributed by 
patients in the histamine subgroup as it was not signi icant in 
the mannitol subgroup. 
In a combined ROC analysis of AHR responders vs. non-
responders (Figure 1a), the AUC value was 0.765 with 
p < 0.001. A FeNO threshold of > 14 ppb was associated with 
a sensitivity of 82% and speci icity of 51% in identifying 
patients with a positive histamine or mannitol challenge 
test. In the histamine subgroup (Figure 1b), AUC was 0.754, 
p < 0.001 while FeNO > 14 ppb resulted in a sensitivity of 80% 
and speci icity of 56%. For the mannitol subgroup (Figure 1c), 
AUC was 0.786; p < 0.001 and FeNO > 16 ppb had a sensitivity 
of 82% and speci icity of 50%. ROC analysis for eosinophils, 
allergic burden, FEV1 or FEF25-75 were not signi icant. 
There were no signi icant differences in blood eosinophils 
for the combined group when comparing AHR positive vs. 
negative patients [315(34) vs. 308(25) cells/μL p = 0.86] 
[mean (SEM)] or for either histamine or mannitol alone. 
Discussion 
Our study demonstrated elevated levels of FeNO and 
speci ic IgE but not blood eosinophils in relation to AHR. 
Moreover, patients with AHR also had altered geometry as 
FEV1 and FEF25-75. We observed that 57% of our patients had a 
positive challenge with either histamine or mannitol. Whether 
or not this infers that the remainder of our patients who were 
challenge negative did not have asthma is debatable. Ideally 
this would require a repeat challenge having had a washout 
period of at least 2 weeks without ICS. AHR non-responders 
received signi icantly higher ICS doses, which is in keeping 
with the known dose related suppressive effects of ICS on 
AHR and type 2 in lammation [16,17]. Non responders also 
had signi icantly better pulmonary function. In this regard 
improved airway calibre would attenuate AHR due to effects 
on airway geometry per se. 
It has previously been shown that FeNO levels are higher 
in patients who exhibit AHR to histamine, methacholine or 
mannitol [7,18,19]. Pointedly our study con irmed this inding 
when looking at patients prescribed ICS. A prospective study 
showed that titrating ICS against mannitol challenge during a 
1 year period was associated with a 1.52 doubling dose shift in 
AHR, which in turn was accompanied by improved symptom 
control and fewer exacerbations [20]. Our results found no 
association between blood eosinophils and AHR which is in 
contrast to previous observations [6]. This may well re lect our 
patients being on a relatively high dose of ICS (mean 858μg) 
which is known to suppress blood eosinophils [21]. FeNO is 
Table 1: Patient demographics.




(ppb)† Combined challenges Histamine PC20  Mannitol PD15  Allergy testing  
Total Sex
 131 
M F     + ve - ve < 8 mg/ml ≥ 8 mg/ml < 635 mg ≥ 635 mg + ve - ve
 45 86 47(1) 92(1) 60(2) 19(2) 75 56 40 35 35 21 73 42
FEV1 = Forced Expiratory Volume in 1 second; FEF25-75 = Forced mid Expiratory Flow rate at 25% to 75% of forced vital capacity; FeNO = Fractional exhaled Nitric Oxide; PC20 = 
Provocative Concentration causing 20% drop in FEV1; PD15 = Provocative Dose causing 15% drop in FEV1; SEM = Standard Error of Mean. †values are presented as means (SEM).
Table 2: FeNO, spirometry and allergy in patients with or without airway hyperresponsiveness. 
 n Age (yr) FEV1 (%) FEF25-75 (%) FeNO (ppb) Allergy
Combined + ve 75 46(2) 90(2)* 56(2)* 26(3)*** 2(0.2)**
Combined - ve 56 49(2) 95(2) 67(3) 10(1) 1.1(0.2)
Histamine + ve 40 43(3) 91(2)* 60(3)* 23(4)*** 2.1(0.3)***
Histamine - ve 35 51(3) 100(3) 72(4) 9(2) 0.8(0.2)
Mannitol + ve 35 49(3) 88(3) 52(4) 31(3)*** 2(0.3)
Mannitol - ve 21 45(4) 88(3) 58(5) 15(2) 1.5(0.4)
Allergy defi ned as number of positive skin prick tests or positive RASTs to specifi c IgE to at least one aeroallergen; values are shown as means (standard error of means) and 
geometric mean for FeNO *p < 0.05; **p < 0.01 and ***p < 0.001.
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primarily regulated by IL13 and therefore indings from our 
study raise the question whether dupilumab, an anti-IL4rα 
biologic therapy, might perhaps have more bene icial effects 
of attenuating AHR than anti-IL5 [22]. 
The present study also demonstrates that airway 
geometry expressed as FEV1 and FEF25-75 is signi icantly 
lower in patients who exhibit AHR. The presence of airway 
remodelling may offer an explanation for the relationship 
between altered airway geometry and AHR, although without 
performing biopsies this assertion is speculative. Indeed, 
airway remodelling can theoretically augment the degree 
of AHR, separate from its well established effect on airway 
caliber [23]. In a prospective study over 2 years when ICS was 
titrated against methacholine AHR, attenuation of basement 
membrane thickness and reduced mucosal eosinophils were 
accompanied by improved AHR along with better lung function 
and symptoms [24]. Evidence to support a disconnect between 
airway calibre and AHR emanates from a study where dose 
related improvements in FEV1 with muscarinic antagonist 
were not accompanied by a shift in histamine AHR [25]. 
Previous studies examining the relationship between 
degree of allergy and AHR have yielded contradicting results 
[26]. We elected to use the number of positive skin prick or 
RAST tests to pragmatically assess speci ic IgE and hence the 
overall allergic load. Our study demonstrated a signi icant 
difference in allergic burden using speci ic IgE according to 
the presence of AHR. 
We recognize the limitations of our retrospective analysis. 
We would have liked to correlate these indings with asthma 
control or number of exacerbations. Our study also raises the 
pertinent question as to whether the presence of a negative 
challenge indicates that the patient does not have asthma or 
whether this might be a false negative result as a consequence 
of treatment modi ication with ICS. We might have stopped 
ICS for at least 2 weeks before performing challenge testing 
in order to address this question. However, concurrent ICS 
therapy is more likely to in luence AHR using direct versus 
indirect challenge [10,20]. For example in one study we 
observed that 30% of unselected patients with community 
managed asthma were challenge negative to either mannitol 
or methacholine [15]. These patients had a high burden 
of treatment exposure with a median beclomethasone 
equivalent daily dose of 1,000 μg along with 68% also taking 
LABA. This in turn might suggest a need for a supervised step 
down protocol to un-diagnose asthma in such patients [27]. 
Figure 1: ROC curves depicting signifi cant diff erences in FeNO levels between patients who are AHR responders and non-responders for groups a) 
combined (histamine and mannitol), b) histamine, and c) mannitol.
Figure 2: Values shown as means and standard error of means (geometric mean for FeNO) for signifi cant comparisons between patients with and 
without AHR according to a) allergy burden, b) FeNO, c) FEV1 % predicted, and d) FEF25-75 % predicted.
A retrospective cohort study to evaluate the relationship of airway hyperresponsiveness to type 2 biomarkers in persistent asthma
https://www.heighpubs.org/haard 012https://doi.org/10.29328/journal.aaai.1001023
Conclusion 
In conclusion, FeNO and allergy but not blood eosinophils 
were signi icantly different when comparing AHR responders 
and non-responders. FeNO had a high sensitivity but low 
speci icity in relation to the presence or absence of AHR.
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